StageAcq - Fin - II | Alive
About U.S. Dermatology Partners
Dermatology Associates provides comprehensive practice management services to 75 board-certified dermatologists across 50 locations in Texas, Kansas and Missouri. Dermatology Associates is focused solely on supporting providers so that they can focus exclusively on delivering high-quality, medically-focused care to patients. By leveraging the benefits of a broad, group platform, Dermatology Associates physicians are able to maintain professional autonomy while the business aspects of practice management are handled by its team of experts.
Missing: U.S. Dermatology Partners's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: U.S. Dermatology Partners's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest U.S. Dermatology Partners News
Oct 17, 2022
ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact email@example.com . Back to Healio U.S. Dermatology Partners has launched a program intended to increase access to clinical trials for diagnostic testing and treatment options, according to a press release. With 36 active trials, the U.S. Dermatology Partners Research Institute is conducting observational studies, interventional trials and device trials. The research centers plan to collaborate with pharmaceutical companies through industry-sponsored clinical studies. U.S. Dermatology Partners has launched a program intended to increase access to clinical trials for diagnostic testing and treatment options. Healio spoke with Lindsay Ackerman, MD, who leads the program. Lindsay Ackerman Healio: Why is this program important? Ackerman: Our program is important for the myriad of patients across different demographics and disease states that otherwise are dealing with conditions for which we need better therapeutic options. At the U.S. Dermatology Partners Research Institute, we’re assessing new molecules as treatments for difficult-to-treat diseases along with investigating therapies already approved for other conditions, for their applicability to the treatment of skin diseases. In addition, we are facilitating the acquisition of disease-specific characteristics, such as RNA patterns , in various inflammatory skin conditions so as to know which therapy may be most effective in a given patient. For example, with psoriasis, we have multiple great therapeutic options. One of the conundrums we find ourselves in is with so many great options, how do we know necessarily which option will be best for an individual patient? I see the future of medicine allowing us to make such decisions more easily, where patient-specific disease characteristics at a more molecular level will be exploited to improve outcomes. This favored trend in medicine is called pharmacogenomics. We’re trying to bridge that gap and understand how best we can apply the given therapies that we have to the given patients for whom it will benefit the most. Healio: What is the impact of this program on practicing clinicians? Ackerman: Those of us clinicians participating in the clinical trials have access to potential therapeutic options for our patients that otherwise are not accessible to other providers for many difficult-to-treat diseases. We have a much broader and more robust armamentarium of choices that we can offer, which can be particularly rewarding in managing those patients whose disease may limit their ability to function with even basic life requirements, such as getting to work, taking care of children, socialization, intimacy, and even avoiding hospitalization, etc. For practicing dermatologists not directly involved in our research, we hope that our work will ultimately allow for them to reach further into a treatment tackle box with more options of greater opportunities for their patients. Healio: What diagnostic and treatment options are being tested in these trials? Ackerman: Diagnostically, one of the things we are working on is looking at less invasive diagnostic techniques for inflammatory skin diseases and skin cancer , so we may not have to cut a hole in someone, that is, biopsy, to come to a diagnosis. We are looking at ways to prevent skin cancer development in our most high-risk populations, such as solid organ transplant recipients, and how to more specifically treat their skin cancers when advanced. As mentioned, we are looking at the molecular makeup of various inflammatory diseases, hoping that these data will allow for a choice of therapy based upon a patient’s specific disease state makeup, rather than just treating a disease by name. And lastly, perhaps of greatest reward in our research efforts, is the work we are doing to explore new treatment options for very difficult-to-treat and very consequential skin disorders. We are working hard to make sure the pipeline of drugs available to treat our patients is both more broad, and more effective. Healio: Anything else? Ackerman: There’s nothing more fulfilling than taking someone from a place where life in all aspects — even sleeping — was uncomfortable, where patients were living, resenting how their disease unfairly affected not just the day-to-day, but the overall trajectory of their life, and giving them a novel option, with, moreover, oftentimes a novel life experience. I’m very grateful for this opportunity being afforded to me. Reference:
U.S. Dermatology Partners Frequently Asked Questions (FAQ)
When was U.S. Dermatology Partners founded?
U.S. Dermatology Partners was founded in 2012.
Where is U.S. Dermatology Partners's headquarters?
U.S. Dermatology Partners's headquarters is located at 1367 Dominion Plaza, Tyler.
What is U.S. Dermatology Partners's latest funding round?
U.S. Dermatology Partners's latest funding round is Acq - Fin - II.
How much did U.S. Dermatology Partners raise?
U.S. Dermatology Partners raised a total of $76.41M.
Who are the investors of U.S. Dermatology Partners?
Investors of U.S. Dermatology Partners include ABRY Partners, Candescent Partners, Harbert Management Corporation and Eagle Private Capital.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.